# Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

> **NCT00030667** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 100 (actual)

## Conditions studied

- Childhood Desmoplastic Small Round Cell Tumor
- Childhood Synovial Sarcoma
- Gastrointestinal Stromal Tumor
- Lung Metastases
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00030667
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030667, "Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00030667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*